Article

Optimal dosing for vascular anomalies pediatric patients with population pharmacokinetic model of sirolimus

2025-05-14

Abstract excerpt

<h4>Aim: </h4> Sirolimus is currently used off-label for pediatric patients with vascular anomalies. However, the optimal dosage regimen for pediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model. <h4>Methods:</h4> Prospective study data (7 subjects) were used as the base model without covariate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 442c1efc-00e2-539c-b1a3-11a036805b08
DOI: 10.22541/au.174724433.39180010/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimal dosing for vascular anomalies pediatric patients with population pharmacokinetic model of sirolimusDOI 10.22541/au.174724433.39180010/v1Read

Long term treatment of sirolimus for pediatric vascular anomalySemantic proximity Read

How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.Semantic proximity Read

Defining vascular anomaly phenotypes in children based on a systematic literature search: A critical step in developing a single severity score for interventional clinical trials.Semantic proximity Read

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read

Alpelisib in pediatric PIK3CA- and TIE-2–mutant vascular anomalies: a case series on safety, efficacy, and drug exposureSemantic proximity Read

Influence of genetic variants on the pharmacokinetics and pharmacodynamics of sirolimus: a systematic review.Semantic proximity Read

Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.Semantic proximity Read

Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.Semantic proximity Read

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.Semantic proximity Read

Application of stochastic simulation-estimation approach to the optimization of Pharmacokinetic studies design in the context of paediatric extrapolation: A step toward better decision making for drug sponsors and regulatorsSemantic proximity Read

Potential anti-arteriovenous malformations effect of sirolimus on angiogenesis induced by maxillofacial venous hypertensionSemantic proximity Read

Age- and sex-specific pediatric LMS-Percentiles for Laboratory Parameters enabled by Data miningSemantic proximity Read